Full-Time

Director – Clinical Quality Assurance

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology

Compensation Overview

$200k - $240kAnnually

Senior, Expert

Remote in USA

Category
QA & Testing
Manual Testing
Quality Assurance
Required Skills
Google Cloud Platform

You match the following BridgeBio's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 2+ years of experience with Veeva administration highly preferred
  • Ability to build relationships and work collaboratively with a variety of individuals within the department, company, and vendors
  • Strong negotiation skills, flexibility, and ability to provide a solution-based approach to emerging challenges
  • A strong team player with the ability to effectively communicate sound quality advice cross-functionally based on experience, regulations, and business needs
  • Ability to simultaneously handle multiple project issues while dealing with time demands, incomplete information, or unexpected events
  • Proficient in discerning, high quality verbal and written communication
  • Bachelor's degree in a scientific discipline or equivalent experience
  • Minimum of 6 years of experience in a GCP practice area; Clinical Quality Assurance or similar role preferred
  • Expertise with applicable GCP guidelines
Responsibilities
  • Proactively define and drive Clinical Controlled Document management strategy at QED, and partner with other BBIO functions as it relates to ‘centralized’ Clinical Controlled Documents
  • Develop, review, and revise Clinical Controlled Documents (eg, SOPs, Work Instructions) to ensure alignment with regulatory standards and industry best practices
  • Manage Clinical Controlled Documents in accordance with format, content and style guidelines, and help ensure accuracy, consistency, and quality
  • Partner with GMP QA in the management of Quality Assurance Controlled Documents
  • Act as a single point of contact (SPoC) for clinical functional areas, and collaborate to manage document workflows
  • Administrate Controlled Document management activities within Veeva including creation, review, approval and archiving processes
  • Monitor workflow status (including follow up if any delay is noted) to document approval
  • Foster a culture of continuous improvement and innovation across the organization
  • Design and develop project specific training programs
  • Administrate training management activities within Veeva, and in partnership with existing Administrators
  • Support mock inspections, identify potential compliance gaps, and implement corrective actions, as needed
  • Other duties as assigned or required

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific therapies while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to bring treatments to market more quickly than traditional biopharma processes. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Stage

IPO

Total Funding

$704.4M

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

4%

1 year growth

3%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investment by Norges Bank shows strong investor confidence in BridgeBio.
  • Partnership with PANTHERx Rare enhances market penetration for rare disease therapies.
  • KRAS inhibitors development positions BridgeBio in a promising cancer treatment market.

What critics are saying

  • Alnylam's RNAi therapy poses competitive pressure on BridgeBio's Attruby.
  • Decentralized model may challenge cohesive strategic direction across programs.
  • Increased competition in KRAS inhibitors could impact BridgeBio's market share.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focus on genetic diseases allows targeting conditions with well-understood genetic causes.
  • Partnerships with specialty pharmacies enhance patient access to rare disease therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off